Michael S. Kay, MD, PhD

Research Interests

  • Virology
  • Protein Design
  • Drug Design
  • Peptides
  • Protein Chemistry
  • Chemical Biology


Lab Website


  • English

Academic Information

  • Departments: Biochemistry - Professor

Academic Office Information

  • 801-585-5021
  • Emma Eccles Jones Medical Research Building
    15 N Medical Dr E, Room: 3240C
    Salt Lake City, UT

Education History

Type School Degree
Postdoctoral Fellowship Massachusetts Institute of Technology
Postdoctoral Fellow
Professional Medical Stanford University
Doctoral Training Stanford University
Undergraduate Cornell University

Selected Publications

Journal Article

  1. Clinton TR, Weinstock MT, Jacobsen MT, Szabo-Fresnais N, Pandya MJ, Whitby FG, Herbert AS, Prugar LI, McKinnon R, Hill CP, Welch BD, Dye JM, Eckert DM, Kay MS (2015). Design and characterization of ebolavirus GP prehairpin intermediate mimics as drug targets. Protein Sci, 24(4), 446-63.
  2. Weinstock MT, Jacobsen MT, Kay MS (2014). Synthesis and folding of a mirror-image enzyme reveals ambidextrous chaperone activity. Proc Natl Acad Sci U S A, 111(32), 11679-84.
  3. Mesquita PM, Srinivasan P, Johnson TJ, Rastogi R, Evans-Strickfaden T, Kay MS, Buckheit KW, Buckheit RW Jr, Smith JM, Kiser PF, Herold BC (2013). Novel preclinical models of topical PrEP pharmacodynamics provide rationale for combination of drugs with complementary properties. Retrovirology, 10(1), 113.
  4. Pang HB, Hevroni L, Kol N, Eckert DM, Tsvitov M, Kay MS, Rousso I (2013). Virion stiffness regulates immature HIV-1 entry. Retrovirology, 10, 4.
  5. Francis JN, Redman JS, Eckert DM, Kay MS (2012). Design of a modular tetrameric scaffold for the synthesis of membrane-localized D-peptide inhibitors of HIV-1 entry. Bioconjug Chem, 23(6), 1252-8.
  6. Denton PW, Othieno F, Martinez-Torres F, Zou W, Krisko JF, Fleming E, Zein S, Powell DA, Wahl A, Kwak YT, Welch BD, Kay MS, Payne DA, Gallay P, Appella E, Estes JD, Lu M, Garcia JV (2011). One percent tenofovir applied topically to humanized BLT mice and used according to the CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection, validating the BLT model for evaluation of new microbicide candidates. J Virol, 85(15), 7582-93.